Encainide C??? ??, ??, ??
??
Clinical use of encainide is primarily associated with the presence of serious ventricular
tachycardia; however, like flecainide, it is also sufficiently effective for atrial arrhythmia
and is used for natural occurrences.
World Health Organization (WHO)
The membrane-stabilizing antiarrhythmic agent encainide was
introduced into medicine in the mid-1980's. The decision to delete the indications
for patients with asymptomatic and less severe symptomatic ventricular
arrhythmias was taken on the basis of the results of a trial (CAST study) that
showed a two-fold increase in deaths in post-myocardiac patients taking encainide
compared with the placebo group. (See also WHO comment for flecainide).
Encainide ?? ?? ? ???
???
?? ??
